Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 461 Next >>

Filter Applied: multiple sclerosis (Click to remove)

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012

MRI Criteria for MS in Patients with Clinically Isolated Syndromes
Neurol 74:427-434, Montalban,X.,et al, 2010

Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009

Picturing Multiple Sclerosis: Conventional and Diffusion Tensor Imaging
Semin Neurol 28:453-466, Fox,R.J., 2008

An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008

Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007

Guidelines For Using Proton MR Spectroscopy in Multicenter Clinical MS Studies
Neurol 69:1942-1952, De Stefano,N.,et al, 2007

Standardized MR Imaging Protocol for Multiple Sclerosis:Consortium of MS Centers Consensus Guidelines
AJNR 27:455-461, Simon,J.H.,et al, 2006

Recommended Standard of Cerebrospial Fluid Analysis in the Diagnosis of Multiple Sclerosis, A Consensus Statement
Arch Neurol 62:865-870, Freedman,M.S.,et al, 2005

Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001

Practice Parameter: The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients With Suspected Multiple Sclerosis (an Evidence-Based Review)
Neurol 54:1720-1725, Gronseth,G.S.&Ashman,E.J., 2000

The Contribution of Magnetic Resonance Imaging to the Diagnosis of Multiple Sclerosis
Neurol 53:448-456, Fazekas,F.,et al, 1999

Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998

A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998

Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020

Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019

Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017

Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017

Incidence of Radiologically Isolated Syndrome: A Population-Based Study
AJNR 37:1017-1022, Forslin, Y.,et al, 2016

The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016

Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015

Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014

Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014

Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014

Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014

The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014

The Thalamus and Multiple Sclerosis
Neurol 80:210-219, Minagar, A.,et al, 2013

Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013

Interdependence and Contributions of Sun Exposure and Vitamin D to MRI Measures in Multiple Sclerosis
JNNP 84:1075-1081, 1066, Zivadinov, R.,et al, 2013

Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis verus Healthy Controls
AJNR 33:252258, Habib,C.A.,et al, 2012

Solitary Sclerosis
Neurol 78:540-544, Schmalstieg,W.F.,et al, 2012

Distinct Lesion Morphology at 7-T MRI Differentiates Neuromyelitis Optica from Multiple Sclerosis
Neurol 79:708-714, Sinnecker, T.,et al, 2012

Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis
Arch Neurol 69:1259-1269, Radue, E.W.,et al, 2012

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012

Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Ann Neurol 69:292-302, 234, Polman,C.H.,et al, 2011

Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Neurol 76:1858-1865, OConnor, P.W.,et al, 2011

Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011

Balos Concentric Sclerosis
NEJM 365:742, Wengert, O.,et al, 2011

Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011

Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011

Inflammatory Cortical Demyelination in Early Sclerosis
NEJM 365:2188-2197, Lucchinetti, C.F.,et al, 2011

Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011

Diffusely Abnormal White Matter in Progressive Multiple Sclerosis: In Vivo Quantitative MR Imaging Characterization and Comparison between Disease Types
AJNR 31:541-548, 390, Vrenken,H.,et al, 2010

Ring and Nodular Multiple Sclerosis Lesions: A Retrospective Natural History Study
Neurol 74:851-858, Davis,M.,et al, 2010



Showing articles 0 to 50 of 461 Next >>